UPDATE: Eiger BioPharmaceuticals (EIGR) Tops Q1 EPS by 19c

May 11, 2018 8:04 AM
(Updated - May 11, 2018 8:07 AM EDT)

Eiger BioPharmaceuticals (NASDAQ: EIGR) reported Q1 EPS of ($0.84), $0.19 better than the analyst estimate of ($1.03).

"The Eiger HDV program is moving into Phase 3 with a single, international, multi-center registration trial of approximately 300 HDV infected patients called D-LIVR (Delta Liver Improvement and Virologic Response in HDV)," said David Cory, President and CEO. "We plan to complete agency discussions and communicate final details of the D-LIVR study by mid-year."

First Quarter 2018 Financial Results

For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.


Earnings Management Comments

Next Articles